medigraphic.com

2012, Number 4

<< Back Next >>

Rev Latinoam Psiquiatría 2012; 11 (4)

Calidad de vida y concentraciones séricas de TNF-α en pacientes mexicanos con tuberculosis y trastorno depresivo mayor

Pezoa JRE, Álvarez SAM, López-Bago MAL, Lascurain LR, Vásquez MJA, Cruz FCS

Language: Spanish
References: 25
Page: 125-132
PDF size: 510.37 Kb.


ABSTRACT

Background: Tuberculosis (TB) is a disease whose presentation depends on host defenses, whereas neuroimmune disregulations are a feature of major depressive disorder (MDD). Tumor Necrosis Factor alpha (TNF-α) plays a role in the pathophysiology of both TB and MDD. These diseases are prevalent in Mexico, however there is scant research addressing their association.
Objective: Evaluate if there are differences in TNF-a levels and quality of life (QoL) between subjects with TB and/or MDD, compared to healthy controls.
Material and Methods: Thirty-seven subjects (MDD=10, TB=9, TB+MDD=8, controls=10) were recruited at the National Institute of Psychiatry and National Institute of Respiratory Diseases. Instruments used were the SCID-I, Beck Depression Inventory, Hamilton Depression Scale and the Brief World Health Organization Quality of Life survey. Blood samples were obtained to assess percentage of mononuclear cells positive for TNF-α.
Results: Highest mean levels of TNF-α were found in the comorbid TB+MDD group (X=10.46, DE=14.59) while the control group had the lowest levels (X=3.26, DE=4.93). However, when comparing all groups, no statistically significant differences were found. Mean QoL scores were lower in the MDD (X=65.6, DE=5.4) and TB+MDD (X=66.2, DE=14.5) groups. When comparing all groups, there were significant differences between TB vs. MDD (p=0.013), TB vs. TB+MDD (p=0.004) and MDD vs. control (p=0.0002) groups.
Conclusion: There were not significant differences across groups regarding TNF-α levels, while subjects with MDD and TB+MDD showed a worse quality of life.


REFERENCES

  1. Leonard BE, Myint A. The psychoneuroimmunology of depression. Hum Psychopharmacol 2009; 24:165-175.

  2. Hansen MS, Fink P, Frydenberg M, Oxhøj ML. Use of health services, mental illness, and self-rated disability and health in medical inpatients. Psychosom Med 2002; 64: 668-675.

  3. Prince M, Patel V, Saxena S, Maj M, Maselko J, Phillips MR, et al. No health without mental health. Lancet 2007; 370:859- 877.

  4. Ziemssen T, Kern S. Psychoneuroimmunology- Cross-talk between the immune and nervous systems. Neurology 2007; 254:II8-II11.

  5. Delves PJ, Roitt IM. Roitt’s essential immunology. 12th ed. Chichester, West Sussex ; Hoboken, NJ: Wiley-Blackwell, 2011.

  6. Nordli DR, Jr, Moshe SL, Shinnar S, Hesdorffer DC, Sogawa Y, Pellock JM, et al. Acute EEG findings in children with febrile status epilepticus: Results of the FEBSTAT study. Neurology 2012.

  7. Zazueta-Beltran J, Leon-Sicairos C, Canizalez-Roman A. Drug resistant Mycobacterium tuberculosis in Mexico. J Infect Developing Countries 2009;3:162-168.

  8. Dobson R, Ramagopalan S, Giovannoni G, Bazelier MT, de Vries F. Risk of fractures in patients with multiple sclerosis: A population-based cohort study. Neurology 2012;79:1934- 1935.

  9. Cecil RL, Goldman L, Ausiello DA. Cecil medicine. 23rd ed. Philadelphia: Saunders Elsevier, 2008.

  10. Bottasso O, Bay ML, Besedovsky H, del Rey A. Immunoendocrine alterations during human tuberculosis as an integrated view of disease pathology. Neuroimmunomodulation 2009;16: 68-77.

  11. Flynn JL, Chan J. Immunology of tuberculosis. Ann Rev Immunol 2001;19: 93-129.

  12. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, et al. Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing Agent. N England J Med 2001;345: 1098-1104.

  13. Sadock BJ, Kaplan HI, Sadock VA. Kaplan & Sadock’s synopsis of psychiatry : behavioral sciences/clinical psychiatry. 10th ed. Philadelphia: Wolter Kluwer/Lippincott Williams & Wilkins, 2007.

  14. Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, Reim EK, et al. A meta-analysis of cytokines in major depression. Biol Psychiatry 2010; 67: 446-457.

  15. Sutcigil L, Oktenli C, Musabak U, Bozkurt A, Cansever A, Uzun O, et al. Pro- and anti-inflammatory cytokine balance in major depression: effect of sertraline therapy. Clin Dev Immunol 2007; 2007.

  16. Trenton AJ, Currier GW. Treatment of comorbid tuberculosis and depression. Prim Care Companion J Clin Psychiatry 2001; 3:236-43.

  17. Issa BA, Yussuf, A.D., Kuranga, S.I. Depression comorbidity among patients with tuberculosis in a university teaching hospital outpatient clinic in Nigeria. Mental Health Fam Med. 2009; 6: 133-138.

  18. Purohit D, Purohit S, Dhariwal M. Incidence of depression in hospitalized T.B. patients. Indian J Tuberculosis 1978; 25: 147-151.

  19. Vega P, et. al. Psychiatric issues in the management of patients with multidrug-resistant tuberculosis. Int J Tuberculosis Lung Dis. 2004;8: 749-759.

  20. Henderson VW, Rocca WA. Estrogens and Alzheimer disease risk: Is there a window of opportunity? Neurology. 2012; 79:1840-1841.

  21. Boylan LS, Flint LA, Labovitz DL, Jackson SC, Starner K, Devinsky O. Depression but not seizure frequency predicts quality of life in treatment-resistant epilepsy. Neurology 2004; 62: 258-261.

  22. Haack M, Hinze-Selch D, Fenzel T, Kraus T, Kühn M, Schuld A, et al. Plasma levels of cytokines and soluble cytokine receptors in psychiatric patients upon hospital admission: effects of confounding factors and diagnosis. J Psychiatr Res 1999;33:407-418.

  23. Liu Y, Ho RC, Mak A. Interleukin (IL)-6, tumour necrosis factor alpha (TNF-alpha) and soluble interleukin-2 receptors (sIL- 2R) are elevated in patients with major depressive disorder: A meta-analysis and meta-regression. J Affect Disord 2011; 139: 230- 239.

  24. Simopoulos A. Genetic variation: nutritional implications. World Rev Nutr Dietetics 2004; 93: 1-28.

  25. Blume J, Douglas SD, Evans DL. Immune suppression and immune activation in depression. Brain Behav Immun 2011; 25: 221-229.




2020     |     www.medigraphic.com